

CLEARBRIDGE HEALTH LIMITED
(the "**Company**")
(Company Registration Number: 201001436C)
(Incorporated in the Republic of Singapore)

APPLICATION FOR WAIVERS FROM RULES 705(1) AND 707(1) OF THE CATALIST RULES

1. The Board of Directors (the "**Board**") of the Company (together with its subsidiaries, the "**Group**") refers to the Company's announcement on 1 March 2023 relating to the Company's application (the "**Initial Application**") to the Singapore Exchange Securities Trading Limited ("**SGX-ST**") for an extension of the deadline under Rule 705(1) of the Listing Manual Section B: Rules of Catalist of the SGX-ST (the "**Catalist Rules**").
2. Under the Catalist Rules:
 - (a) Rule 705(1) requires the Company to announce its unaudited full year financial statements of the Group (the "**FY2022 Financial Statements**") for the financial year ended 31 December 2022 ("**FY2022**") by no later than 1 March 2023 (the "**FY2022 Financial Statements Deadline**"); and
 - (b) Rule 707(1) requires the annual general meeting ("**AGM**") of the Company (the "**FY2022 AGM**") in relation to FY2022 to be held no later than 30 April 2023 (the "**FY2022 AGM Deadline**").
3. The Board wishes to announce that the Company has, on the same date as this announcement, withdrawn the Initial Application and made a new application ("**Waiver Application**") to the SGX-ST to seek:
 - (a) a three-month extension of the FY2022 Financial Statements Deadline under Rule 705(1) of the Catalist Rules, to announce the FY2022 Financial Statements by 31 May 2023; and
 - (b) a 60-day extension of the FY2022 AGM Deadline under Rule 707(1) of the Catalist Rules, to hold the FY2022 AGM by 29 June 2023,(collectively, the "**Waivers**").

A. REASONS FOR THE WAIVER APPLICATION

4. The Company sought the Waivers because, as of the date of the Waiver Application, the Company has not been able to finalise its FY2022 Financial Statements as it is pending access by Lunadorii Inc. ("**Lunadorii**") to the necessary financial information of PT Tirta Medika Jaya ("**TMJ**") and PT Indo Genesis Medika ("**IGM**"). TMJ and IGM were both previously indirect subsidiaries of the Company prior to the Company's disposal of 100% of its shareholding interests in Clearbridge Medical Asia Pte. Ltd. ("**CBMA**") and SAM Laboratory Pte. Ltd. ("**SAM**") to Lunadorii on 7 October 2022 (the "**Disposal**") which hold TMJ and IGM respectively.

5. Lunadorii has informed the Company that it has not been able to access the necessary financial information of TMJ and IGM in a timely manner for the purpose of finalising the Company's FY2022 Financial Statements and requires more time to do so because at the time of completion of the Disposal on 7 October 2022, the management accounts of TMJ and IGM for the financial period commencing 1 July 2022 to 30 September 2022; and up until the date of the Disposal on 7 October 2022 were not yet available. Since the Disposal on 7 October 2022, the Company has had difficulty accessing the necessary financial information through Lunadorii due to the lack of cooperation from the staff of TMJ and IGM during the related transition process.
6. The Company has continuously reached out to Lunadorii to request for the necessary financial information of TMJ and IGM and has requested for updates regarding the status of access to the necessary financial information. As at the date of the Waiver Application, the Company understands that Lunadorii has made progress towards obtaining the necessary financial information through the following actions:
 - (a) On 12 December 2022, Lunadorii obtained statutory control of the board of directors and board of commissioners of IGM by appointing its nominee directors to the respective boards. As a result, the nominee directors appointed by Lunadorii now form the entire board of directors and board of commissioners at IGM. The nominee directors appointed by Lunadorii are in the process of changing the authorised signatories of IGM by approaching the respective banks of IGM.
 - (b) Following the lack of cooperation of the staff of IGM in providing access to the necessary financial information, Lunadorii has hired key executives and formed a team to take over the day-to-day management of IGM. On 16 and 20 March 2023, IGM published advertisements in the national newspaper, Media Indonesia, to inform third parties of the change in the board of directors and the board of commissioners at IGM. Lunadorii believes that the new key executives and the new management team at IGM will mitigate disruptions to its operations.
7. As a result of the above, the Company will need more time for the finalisation and release of the FY2022 Financial Statements, the finalisation and release of the Company's annual report for FY2022 (containing the FY2022 Financial Statements and the relevant auditor's report) and the necessary preparations for the FY2022 AGM.
8. The Company has concurrently submitted an application to the Accounting and Corporate Regulatory Authority for an extension of time to convene the FY2022 AGM and to lay its financial statements for FY2022 at the FY2022 AGM, and to file its annual return for FY2022.
9. The Board will issue further announcements as appropriate, as and when there are further updates to the Waiver Application.

BY ORDER OF THE BOARD

Yee Pinh Jeremy

Executive Director and Chief Executive Officer

20 March 2023

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalyst. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*